KRAS inhibitor-3

• CAT Number: I041817
• CAS Number: 900897-56-5
• Molecular Formula: C25H27N5O
• Molecular Weight: 413.51
• Purity: ≥95%
• Synonyms: 2-[4-(2-methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)piperazin-1-yl]ethanol
• InChI: InChI=1S/C25H27N5O/c1-19-24(21-10-6-3-7-11-21)25-26-22(20-8-4-2-5-9-20)18-23(30(25)27-19)29-14-12-28(13-15-29)16-17-31/h2-11,18,31H,12-17H2,1H3
• InChIKey: MTHOJIJARWDIJS-UHFFFAOYSA-N
• SMILES: CC1=NN2C(=CC(=NC2=C1C3=CC=CC=C3)C4=CC=CC=C4)N5CCN(CC5)CCO

KRAS inhibitor-3 is an inhibitor of KRAS inhibitor. KRAS inhibitor-3 binds to WT and oncogenic KRAS mutants with high affinity (KD: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, 0.74 μM for KRAS Q61H). KRAS inhibitor-3 also disrupts interaction of KRAS with Raf[1].
KRAS inhibitor-3 (Compound 11, 0-1 μM, 72 h) inhibits growth of KRAS-expressing lung cancer cells[1].
KRAS inhibitor-3 (0-5 μM) decreases the p-ERK levels in BHK cells stably expressing KRASG12D[1].
KRAS inhibitor-3 (1 μM, 2 h) disrupts interaction of KRAS with Raf[1].
KRAS inhibitor-3 (0-5 μM) decreases both p-ERK and p-cRaf levels in BHK cells expressing KRASG12D and KRASG12V[1].

Reference

[1]. McCarthy MJ, et al. Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding. ACS Omega. 2019 Feb 28;4(2):2921-2930.
 [Content Brief]